Please enter your license information:
Jentadueto®
![Jentadueto® (linagliptin/metformin HCl). Jentadueto® (linagliptin/metformin HCl).](https://pro.boehringer-ingelheim.com/ca/products/trajenta/images/jentadueto_logo.png)
Jentadueto®: Single pill combination.
Linagliptin and metformin combined in a convenient, single, small tablet15
![2.5/500 mg Jentadueto® tablet
2.5/850 mg Jentadueto® tablet
2.5/1000 mg Jentadueto® tablet
2.5/500 mg Jentadueto® tablet
2.5/850 mg Jentadueto® tablet
2.5/1000 mg Jentadueto® tablet](https://pro.boehringer-ingelheim.com/ca/products/trajenta/images/jentadueto-tablets.png)
![2.5/500 mg Jentadueto® tablet 2.5/500 mg Jentadueto® tablet](https://pro.boehringer-ingelheim.com/ca/products/trajenta/images/jentadueto-tablet-1.png)
![2.5/850 mg Jentadueto® tablet 2.5/850 mg Jentadueto® tablet](https://pro.boehringer-ingelheim.com/ca/products/trajenta/images/jentadueto-tablet-2.png)
![2.5/1000 mg Jentadueto® tablet 2.5/1000 mg Jentadueto® tablet](https://pro.boehringer-ingelheim.com/ca/products/trajenta/images/jentadueto-tablet-3.png)
There have been no clinical efficacy studies conducted with Jentadueto®. However, bioequivalence of Jentadueto® to co-administered linagliptin and metformin hydrochloride tablets was demonstrated in healthy subjects.
- The maximum recommended dose is 2.5 mg/1000 mg BID
Jentadueto® (linagliptin/metformin hydrochloride tablets) is indicated as an adjunct to diet and exercise, to improve glycemic control in adult patients with type 2 diabetes mellitus who are inadequately controlled on metformin, or already controlled with the free combination of linagliptin and metformin.
Jentadueto® (linagliptin/metformin hydrochloride tablets) is indicated as an adjunct to diet and exercise, to improve glycemic control in adult patients with type 2 diabetes mellitus in combination with a sulfonylurea, when dual therapy with metformin and a sulfonylurea do not provide adequate glycemic control, or in combination with basal insulin, when dual therapy with metformin and basal insulin do not provide adequate glycemic control.
Please refer to the Product Monograph at www.JentaduetoPM.ca for contraindications, warnings, precautions, adverse reactions, interactions, dosing and conditions of clinical use. The Product Monograph is also available by calling 1-800-263-5103 ext. 84633.
Are you thinking Trajenta®?
![Healthcare professional and patient Healthcare professional and patient](https://pro.boehringer-ingelheim.com/ca/products/trajenta/images/login-banner-updated.png)
Are you a Canadian
View coverage details for Trajenta® and Jentadueto®
![Map of Canada Map of Canada](https://pro.boehringer-ingelheim.com/ca/products/trajenta/images/check-coverage-icon.png)